Cargando…

The role of the microbiome in NAFLD and NASH

Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of cardiometabolic syndrome, which often also includes obesity, diabetes, and dyslipidemia. It is rapidly becoming the most prevalent liver disease worldwide. A sizable minority of NAFLD patients develop nonalcoholic steatohepatit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolodziejczyk, Aleksandra A, Zheng, Danping, Shibolet, Oren, Elinav, Eran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365925/ https://www.ncbi.nlm.nih.gov/pubmed/30591521 http://dx.doi.org/10.15252/emmm.201809302

Ejemplares similares

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

Bile acids in glucose metabolism in health and disease
por: Shapiro, Hagit, et al.
Publicado: (2018)

Non-alcoholic fatty liver and the gut microbiota
por: Bashiardes, Stavros, et al.
Publicado: (2016)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Inflammasome activation and regulation: toward a better understanding of complex mechanisms
por: Zheng, Danping, et al.
Publicado: (2020)

Interaction between microbiota and immunity in health and disease
por: Zheng, Danping, et al.
Publicado: (2020)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Use of Metatranscriptomics in Microbiome Research
por: Bashiardes, Stavros, et al.
Publicado: (2016)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Local and systemic effects of microbiome‐derived metabolites
por: Spivak, Igor, et al.
Publicado: (2022)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
por: Jadhav, Kavita, et al.
Publicado: (2020)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Metagenomic cross-talk: the regulatory interplay between immunogenomics and the microbiome
por: Levy, Maayan, et al.
Publicado: (2015)

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
por: Finotti, Michele, et al.
Publicado: (2021)

The NLRP6 inflammasome
por: Zheng, Danping, et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

The Gut Microbiome and Individual-Specific Responses to Diet
por: Leshem, Avner, et al.
Publicado: (2020)

The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
por: Song, Qian, et al.
Publicado: (2022)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Involvement of Intracellular TAGE and the TAGE–RAGE–ROS Axis in the Onset and Progression of NAFLD/NASH
por: Sakasai-Sakai, Akiko, et al.
Publicado: (2023)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

Utilization of Host and Microbiome Features in Determination of Biological Aging
por: Ratiner, Karina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bh2jqafcnoj5a433uvmsfvqger